[1] |
WANG Xinshuang, AN Yajuan, GUAN Xiuju, LI Jiao, LIU Yue, WEI Liping, QI Xin.
Study of magnesium isoglycyrrhizinate in ameliorating cisplatin induced myocardial injury in rats
[J]. Tianjin Medical Journal, 2024, 52(8): 809-814.
|
[2] |
QIN Hanlin, HU Changlu, ZHAO Yamei, NIU Weina.
Effect and safety of quadruple regimen in preventing multi-day cisplatin-based chemotherapy induced nausea and vomiting
[J]. Tianjin Medical Journal, 2024, 52(8): 835-839.
|
[3] |
GENG Yongzhi, YANG Li, LI Guowei, ZHANG Jintao, CHENG Xiaolei, TAN Liduan.
Study on the improvement effect and mechanism of nobiletin on rats with acute kidney injury
[J]. Tianjin Medical Journal, 2023, 51(5): 498-503.
|
[4] |
YI Wanping, MA Deshou.
High-intensity focused ultrasound enhances cisplatin chemotherapy sensitivity of breast cancer through TRIF-mediated ERK pathway
[J]. Tianjin Medical Journal, 2022, 50(7): 698-706.
|
[5] |
YU Kuiyang, LIU Pan, ZHANG Haowen, QIN Tao, HU Mingxing△.
Study on the mechanism of LncRNA ZFAS1 targeting miR-373 to induce cisplatin resistance in hepatocellular carcinoma cells
[J]. Tianjin Medical Journal, 2022, 50(5): 455-460.
|
[6] |
MA Zhi, WANG Xinshuang, LIU Yue, WEI Liping, QI Xin.
The protective mechanism of differential isomers of glycyrrhetinic acid on cisplatin-induced H9c2 cardiomyocyte injury
[J]. Tianjin Medical Journal, 2022, 50(12): 1264-1269.
|
[7] |
ZHANG Ni, JIAN Jiu-ying, WANG Xiao-xiao, YU Ting, CHEN Si-yu, GUO Bing, LIU Li-rong .
Study on the correlation between histone methyltransferase 2 and cisplatin-induced
inflammation in chronic kidney disease
[J]. Tianjin Medical Journal, 2021, 49(10): 1048-1052.
|
[8] |
HAN Jian-qiu, HAO Li-hui, XING Ya-ling, ZHANG Yan, WU Wei-guang△.
Long noncoding RNA HOST2 regulates the sensitivity of human ovarian carcinoma SKOV3
cells to cisplatin through PI3K/Akt pathway
[J]. Tianjin Medical Journal, 2020, 48(6): 512-516.
|
[9] |
CHEN Yan, NIU Xiu-long, YU Chun-yan, LI Yan, DENG Wei-min.
The mechanisms of IL-17A promoting the cisplatin-based drug resistance of ovarian cancer in vivo
[J]. Tianjin Medical Journal, 2020, 48(3): 187-190.
|
[10] |
LU Hai-tao△, LI Xue-fei, LIU Li-jun, HE Lei, DUAN Xin-suo.
The effect of T-cadherin combined with cisplatin on cisplatin resistant malignant melanoma cell line
[J]. Tianjin Med J, 2019, 47(5): 459-463.
|
[11] |
LIU Dan, TANG Zhi-ming, WU Fu-yun, ZHAO Hong-yan, KE Jing, XIANG Peng, JIN Jia-qing, LI Shan.
The molecular mechanism of PDCD4 knockdown facilitating cisplatin resistance in
gastric cancer through pAKT/pGSK3β pathway
[J]. Tianjin Medical Journal, 2019, 47(5): 454-458.
|
[12] |
WU Ai-lin, HAN Bin, PENG Jia-yuan, ZHU Yan-feng, PENG Xiao-li, OU Yu, YU Xiao-ping.
The inhibitory effect and molecular mechanism of delphindin on HER-2 positive breast cancer
[J]. Tianjin Medical Journal, 2018, 46(9): 910-915.
|
[13] |
GU Zhenkun, REN Yuanyuan, DU Xiaolang, WANG Chen△.
Research progress on the anti-tumor differentiation effects of zoledronic acid in breast cancer
[J]. Tianjin Med J, 2016, 44(9): 1177-1180.
|
[14] |
WU Yuan1, GU Jiwei2, JING Hongying2, GUO Yuzhi2, WANG Jing2, YAN Chengyun1,2△.
Inhibition effects of paclitaxel/NLS-KALA-SA nanoparticles on A549 cell line in vitro
[J]. Tianjin Med J, 2016, 44(2): 142-145.
|
[15] |
WEN Shuang1, YANG Xiaoyu2, ZHANG Min1, CHU Xiufeng1, ZHONG Genshen3, JI Yinghua1△, LU Ping1△.
The effect of miRNA-7 on chemoresistance in esophageal cancer cell TE-1
[J]. Tianjin Med J, 2016, 44(2): 155-158.
|